Skip to main content

Tweets

Mastery of knee arthrocentesis for internal medicine resident Brian D. Jaros, MD, presents his poster at RWCS 2024. https://t.co/xFoEGnj2QH https://t.co/DpW07jJTLf
Dr. John Cush @RheumNow ( View Tweet )
4 weeks ago
EGPA: Benralizumab (BEN) or Mepolizumab (MEP) A multicenter, double-blind, phase 3, randomized, active-controlled trial has shown that BEN was noninferior to MEP for the induction of remission of patients with relapsing or refractory EGPA. https://t.co/1F8hBCOaFV https://t.co/smTSIY1HA3
Dr. John Cush @RheumNow ( View Tweet )
4 weeks ago
Behçet’s Syndrome A comprehensive overview of Behcet's syndrome appeared in last week's NEJM, reviewing the numerous advances in the immunogenetics, syndrome recognition, and targeted therapeutic approaches. https://t.co/sLgoCRAavP https://t.co/NibyFpPzmW
Dr. John Cush @RheumNow ( View Tweet )
4 weeks ago
Neonatal Fc receptor mAb (lowers Igs) development: 2021 FDA approved efgartigimod (Vyvgart) for myasthenia gravis 2023 FDA approved rozanolixizumab (Rystiggo) for MG 2023 nipocalimab promising efficacy in RA, Sjogrens, hemolytic anemia, MG INTERESTING? https://t.co/Ou9An9EvUK https://t.co/XDDELNAYYD
Dr. John Cush @RheumNow ( View Tweet )
4 weeks ago

PAPA (pyogenic arthritis, pyoderma gangrenosum & acne) syndrome is a hereditary autoinflammatory Dz caused by dominant mutation in PSTPIP1 (triggers IFN-γ-mediated pyrin induction & IL-18 release; can be Tx by JAK inhibition) https://t.co/fy0MnwDA5U https://t.co/l8n2EwgV0t

Dr. John Cush @RheumNow ( View Tweet )
4 weeks ago
FDA approves 10th adalimumab biosimilar - called Simlandi (adalimumab-ryvk), from Alvotech and Teva. Unique in that it's the 1st high-concentration, citrate-free & interchangeable ADA biosimilar.https://t.co/V6zbCnpfvn https://t.co/igLddGMcoM
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Norway study 1558 chart-reviewed SLE cases; 797 were new-onset SLE from 1999 to 2017. During this period the annual SLE incidence rates fell; mostly pronounced in women 50-59 yrs (fell 3.4 to 1.1 per 100K) - paralleled by 74% reduction menopausal HRT https://t.co/zYkXAnEcOI https://t.co/oaz9t65zZy
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Australian study shows self-reported difficulties w/ ambulation (limited<=1 km) had a higher risk of hip and spinal fractures (32% to 219% more)/ Included 239 000 adults >45 yrs https://t.co/IWvKmPc2t8 https://t.co/CDYDzhMUoa
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
When Meningitis Strikes Twice Amanda Moyer, MD, presents her poster at RWCS 2024. https://t.co/er2E2XnrZZ https://t.co/vwDopOLPRH
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
With New Medications Come New Myopathies Alexia Hwang, MD, presents her poster at RWCS 2024. https://t.co/BjYxKk2QlW https://t.co/vDA0dllMQz
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Immunosuppression Increasing Dr. Jack Cush reviews the news and journal reports from the past 2 weeks on https://t.co/V10S4oVFsv; but begins with a discussion of what constitutes "immunosuppression" and how it applies to our patients. https://t.co/KvZIiKowox https://t.co/cbBYydVQbB
Dr. John Cush @RheumNow ( View Tweet )
1 month ago
Single center study of 163 pts (mostly RA) Rx w/ tocilizumab found 41 hospitalized & 49% for serious infx. SIE were more common w/ eosinopenia (EC < 0.05 g/L; avg (0.06 vs 0.20 g/L) & low ratio EC/NC ratio (× 1000 < 11.8) (median (6.54 vs 48.50). https://t.co/88sbHBIhXt https://t.co/6wUeqSbVxx
Dr. John Cush @RheumNow ( View Tweet )
1 month ago